BAM
PCRX icon

Belpointe Asset Management’s Pacira BioSciences PCRX Stock Holding History

Belpointe Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-170
Closed -$6.94K – 2517
2023
Q1 		$6.94K Buy
+170
New +$6.76K ﹤0.01% 2889

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Belpointe Asset Management's PCRX Position: Q2 2023 in Review

Belpointe Asset Management sold out of Pacira BioSciences (PCRX) in Q2 2023, closing a stake of 170 shares — an estimated $6.94K sold.

Belpointe Asset Management first reported a position in PCRX in Q1 2023 and held it in 1 quarter. The position peaked at $6.94K in Q1 2023. 258 funds tracked by Wall St. Rank hold PCRX as of Q2 2023.

  • Belpointe Asset Management reported no remaining Pacira BioSciences position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 170 Pacira BioSciences shares in Q2 2023, an estimated $6.94K.
  • Belpointe Asset Management first reported a position in Pacira BioSciences in Q1 2023 and held it in 1 quarter.
  • Belpointe Asset Management's Pacira BioSciences position peaked at $6.94K in Q1 2023.
  • 258 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.